Source facts
FDA issued an approval letter for ARIKAYCE KIT on 2026-06-29. The source metadata identifies NDA 207356 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
ARIKAYCE KIT — FDA Approval Letter (NDA 207356)
Issued to INSMED INC. Application is approved as submitted.
Issued
June 29, 2026Application
NDA 505b1 • 207356
Product
ARIKAYCE KIT
Company
INSMED INC
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for ARIKAYCE KIT?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: NDA 207356.
- 3Submission: supplement.
- 4Sponsor: INSMED INC.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the ARIKAYCE KIT approval letter
Is ARIKAYCE KIT FDA approved?
This letter documents an FDA approval action: FDA approved NDA 207356 for ARIKAYCE KIT, sponsored by INSMED INC, on June 29, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is NDA 207356?
NDA 207356 is the application under which FDA issued this approval letter for ARIKAYCE KIT to INSMED INC. The letter is dated June 29, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.